粒细胞集落刺激因子促进肝脏再生的机制-传染病信息.PDF

传染病信息  2016年４月30日  第29卷  第２期  Infect Dis Info, Vol. 29, No. ２, April 30, 2016  ·125· hepatic function and in subjects with mild, moderate and severe inhibitor TMC435 and the immunosuppressivescyclosporine and hepatic impairment ［J ］. Hepatology, 2012, 56(Suppl1):555A- tacrolimus ［J ］. Hepatology, 2012, 56(Suppl 4):231A. 556A. [33] Bifano M, Sevinsky H, Stonier M, et al. Daclatasvir, an HCV NS5A [26] Kirby B, Mathias A, Rossi S, et al . No clinically significant replication complex inhibitor, has minimal effect on pharmacokinetic drug interactions between sofosbuvir (GS-7977) pharmacokinetics of midazolam, a sensitive probe for cytochrome and HIV antiretroviralsAtripla (R), rilpivirine, darunavir/ritonavir, P450 3A4 ［EB/OL ］. ［2015-10-16 ］. http://regist2.virology- or raltegravir in healthy volunteers ［J ］. Hepatology, 2012, /2013/8hepcam/docs/21_Bertz.pdf. 56(Suppl1):1067A. [34] Bifano M, Hwang C, Oosterhuis B, et al . Assessment of [27] Dumond JB, Vourvahis M, Rezk NL, et al. A phenotype-genotype pharmacokinetic interactions of the HCV NS5A replication approach to predicting CYP450 and P-glycoprotein drug complex inhibitor daclatasvir with antiretroviral agents: ritonavir- interactions with the mixed inhibitor/inducer tipranavir/ritonavir boosted atazanavir, efavirenz and tenofovir ［J ］. Antivir Ther, ［J ］. ClinPharmacol Ther, 2010, 87(6):735-742. 2013, 18(7):931-940. [28] FDA. FDA Drug Safety Communication: FDA warns of serious